FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KASINGER JAMES R.
2. Issuer Name and Ticker or Trading Symbol

CRISPR Therapeutics AG [ CRSP ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
General Counsel and Secretary
(Last)          (First)          (Middle)

C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET
3. Date of Earliest Transaction (MM/DD/YYYY)

3/10/2020
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $44.67 3/10/2020  A   35000     (1)3/10/2030 Common Shares 35000 $0.00 35000 D  
Restricted Stock Units  (2)3/10/2020  A   8500     (3) (3)Common Shares 8500 $0.00 8500 D  

Explanation of Responses:
(1) This option was granted on March 10, 2020 with respect to 35,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020.
(2) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
(3) This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
KASINGER JAMES R.
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE, MA 02139


General Counsel and Secretary

Signatures
/s/ Michael Esposito, attorney-in-fact3/12/2020
**Signature of Reporting PersonDate

CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more CRISPR Therapeutics Charts.
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more CRISPR Therapeutics Charts.